Reaction Details Report a problem with these data
Target
Mitogen-activated protein kinase 9
Ligand
BDBM50352621
Substrate
n/a
Meas. Tech.
ChEMBL_767487 (CHEMBL1825599)
IC50
10±n/a nM
Citation
Bowers, S; Truong, AP; Jeffrey Neitz, R; Hom, RK; Sealy, JM; Probst, GD; Quincy, D; Peterson, B; Chan, W; Galemmo, RA; Konradi, AW; Sham, HL; Tóth, G; Pan, H; Lin, M; Yao, N; Artis, DR; Zhang, H; Chen, L; Dryer, M; Samant, B; Zmolek, W; Wong, K; Lorentzen, C; Goldbach, E; Tonn, G; Quinn, KP; Sauer, JM; Wright, S; Powell, K; Ruslim, L; Ren, Z; Bard, F; Yednock, TA; Griswold-Prenner, I Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration. Bioorg Med Chem Lett 21:5521-7 (2011) [PubMed] Article
More Info.:
Target
Name:
Mitogen-activated protein kinase 9
Synonyms:
JNK-55 | JNK2 | JNK2/JNK3 | MAPK9 | MK09_HUMAN | Mitogen-Activated Protein Kinase 9 (JNK2) | Mitogen-activated protein kinase 8/9 | PRKM9 | SAPK1A | Stress-activated protein kinase JNK2 | c-Jun N-terminal kinase 2 | c-Jun N-terminal kinase 2 (JNK2)
Type:
Enzyme
Mol. Mass.:
48131.49
Organism:
Homo sapiens (Human)
Description:
JNK-2 was purchased from Upstate Cell Signaling Solutions (formerly Upstate Biotechnology).
Residue:
424
Sequence:
MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRPFQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIHMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQLGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSKMLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEVMDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR